Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
25 Mai 2023 - 1:01PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN
PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May, 2023.
Commission File Number: 001-40530
GH Research PLC
(Exact name of registrant as specified in its
charter)
Joshua Dawson
House
Dawson Street
Dublin 2
D02 RY95
Ireland
(Address of principal
executive office)
Indicate by check
mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
On May 23, 2023,
a manuscript titled “A Phase 1/2 Trial to Assess Safety and Efficacy of a Vaporized 5-Methoxy-N,N-Dimethyltryptamine Formulation
(GH001) in Patients with Treatment-Resistant Depression” was accepted for publication in Frontiers in Psychiatry. The manuscript
describes the results of our completed phase 1/2 clinical trial in patients with treatment-resistant depression (GH001-TRD-102, NCT04698603).
The abstract is available on the publisher’s website. The final, formatted version of the manuscript will be published in due course.
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
GH Research PLC |
Date: May 25, 2023 |
|
|
|
|
By: |
/s/ Julie Ryan |
|
Name: |
Julie Ryan |
|
Title: |
Vice President, Finance |
GH Research (NASDAQ:GHRS)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
GH Research (NASDAQ:GHRS)
Historical Stock Chart
Von Jun 2023 bis Jun 2024